Apatinib promotes apoptosis of the SMMC-7721 hepatocellular carcinoma cell line via the PI3K/Akt pathway.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

15 citing papers in PubMed.

1. Efficacy and safety of apatinib versus sorafenib/placebo in first-line treatment for intermediate and advanced primary liver cancer: A systematic review and meta-analysis.Frontiers in pharmacology · 2023
   Review
2. Apatinib inhibits the growth of small cell lung cancer via a mechanism mediated by VEGF, PI3K/Akt and Ki-67/CD31.Journal of cellular and molecular medicine · 2021
   Article
3. Stimulator of interferon response cGAMP interactor overcomes ERBB2-mediated apatinib resistance in head and neck squamous cell carcinoma.Aging · 2021
   Article
4. Apatinib combined with concurrent chemoradiotherapy in patients with subglottic small cell carcinoma: a case report.The Journal of international medical research · 2021
   Article
5. Targeting ERK combined with apatinib may be a promising therapeutic strategy for treating oral squamous cell carcinoma.American journal of cancer research · 2021
   Article
6. Apatinib-Induced Hand-Foot Skin Reaction in Chinese Patients With Liver Cancer.Frontiers in oncology · 2021
   Review
7. Apatinib as an alternative therapy for advanced hepatocellular carcinoma.World journal of hepatology · 2020
   Review
8. Silencing of circRACGAP1 sensitizes gastric cancer cells to apatinib via modulating autophagy by targeting miR-3657 and ATG7.Cell death & disease · 2020
   Article
9. Apatinib-induced NF-κB inactivation sensitizes triple-negative breast cancer cells to doxorubicin.American journal of translational research · 2020
   Article
10. Apatinib, a Novel Tyrosine Kinase Inhibitor, Promotes ROS-Dependent Apoptosis and Autophagy via the Nrf2/HO-1 Pathway in Ovarian Cancer Cells.Oxidative medicine and cellular longevity · 2020
    Article
11. Celastrol Enhances the Anti-Liver Cancer Activity of Sorafenib.Medical science monitor : international medical journal of experimental and clinical research · 2019
    Article
12. Significant response of low-dose apatinib monotherapy in brain metastases of triple-negative breast cancer: A case report.Medicine · 2019
    Article
13. Dynamics study on the role of curcumin on TGF-β1 expression and pathological changes in acute paraquat poisoned rats.Experimental and therapeutic medicine · 2018
    Article
14. Apatinib-induced protective autophagy and apoptosis through the AKT-mTOR pathway in anaplastic thyroid cancer.Cell death & disease · 2018
    Article
15. Progress in the treatment of solid tumors with apatinib: a systematic review.OncoTargets and therapy · 2018
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

5 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

Indexed as